The Centre for Phenogenomics

Who We Are

Owned & Operated by

Mount Sinai Hospital
Sinai Health System
Joseph & Wolf Lebovic Health Complex

SickKids®

Facility Partner for Infection & Inflammation Core

McGill
McGill University Research Centre on Complex Traits

Operations & Maintenance Funding Partners

INNOVATION.CA
CANADA FOUNDATION FOR INNOVATION | FONDATION CANADIENNE POUR L'INNOVATION

GenomeCanada

Ontario Genomics

The Team

Number of full-time equivalent (FTE)*	2017-2018
Administrative personnel	18.2
Technical and scientific personnel	97.3

By The Numbers

The Budget





Our Customers



What We Do


Infection & Inflammation
Pathology
Clinical Phenotyping
Cryopreservation & Recovery
Imaging
Accelerating discoveries.
From nose to tail.
Model Production
Animal Holding

The Impact We Can Make

July to December 2016
- TCP provides services and data to support Fabry disease project

January 2017
- Manuscript submitted for publication

Molecular Therapy
Methods & Clinical Development
Original Article

AMERICAN SOCIETY of GENE & CELL THERAPY

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34$^+$ Cells fo

Ju Huang,[1] Aneal Khan,[2] Bryan
Michel Boutin,[7] Michael Rothe,[
Axel Schambach,[8,10] Armand K
C. Anthony Rupar,[9] Christiane

[1]University Health Network, Toronto, ON M
Medicine, University of Calgary, Calgary, AB
1A8, Canada; [4]Department of Medical Bioph

In Vivo Toxicology Study of Our Therapeutic Product: LV/AGA-Transduced Fabry Patient CD34$^+$ Hematopoietic Cells

To investigate the potential in vivo toxicity of the LV/AGA-transduced Fabry patient CD34$^+$ hematopoietic cell product, we used our NSF mouse model for an additional xenograft study. To do this under optimal conditions, the NSF mouse line was re-derived at the Toronto Centre for Phenogenomics (TCP) behind a barrier, and a cohort of 7-week-old mixed-gender mice was selected for these experiments. CD34$^+$ hematopoietic cells isolated from a Fabry patient (no. 15-220) were transduced overnight with vehicle (mock) or LV/AGA at an MOI of 10, and 1×10^6 cells were infused into recipient mice 1 day after they were irradiated and treated with antibody against mouse CD122.[15] Half of the mice were killed on day 7, and the remainder were killed on day 28. Mouse weight, body and dermal condition, general appearance, behavior, metabolic parameters, and complete blood counts were assessed.

The Impact We Can Make

July to December 2016
- TCP provides services and data to support Fabry disease project

January 2017
- Manuscript submitted for publication

April to May 2017
- Feedback from the customer

Dear TCP:
Our clinical trial submission for Fabry disease was recently approved by Health Canada! The mouse toxicology study done by your facility was included in our CTA application. Thank you again for all your good work!’

The Impact We Can Make

July to December 2016
- TCP provides services and data to support Fabry disease project

January 2017
- Manuscript submitted for publication

April to May 2017
- Feedback from the customer

October 2017
- Results of Fabry disease Phase I clinical trial released

AVROBIO Company | Pipeline | Patients | Technology | Careers | Investors | Contact | Vector Space Blog

Press Releases

AVROBIO Reports Six-Month Data Showing First Patient Treated for Fabry Disease Achieved Normal Plasma Enzyme Activity with AVR-RD-01 Gene Therapy

First patient with Fabry disease who received a single dose of lentiviral gene therapy achieved normal plasma α-galactosidase A enzyme activity within 45 days and has maintained those levels for six months

Data presented at 59th Annual Meeting of Japanese Society for Inherited Metabolic Diseases

Cambridge, MA, October 12, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced initial six-month clinical data from the first patient treated with AVR-RD-01, its lentiviral gene

The Impact We Can Make

July to December 2016
- TCP provides services and data to support Fabry disease project

January 2017
- Manuscript submitted for publication

April to May 2017
- Feedback from the customer

October 2017
- Results of Fabry disease Phase I clinical trial released

June 2018
- Initial Public Offering